Rhythm Biosciences Ltd (ASX: RHY) has successfully completed a significant portion of the geneType™ integration following its acquisition on December 24, 2024. This milestone marks a major step in restoring commercial operations and positioning the company for future growth.
Key Integration Achievements
✔ Commercial Processes Restored – Rhythm can now fully offer the geneType™ product portfolio.
✔ Key Personnel Retained – Specialists supporting geneType™ have transitioned seamlessly.
✔ Critical Partnerships Re-established – Agreements with Nest Genomics and DNAnexus secured.
✔ Regulatory Approvals Secured – Permits and licences successfully transferred.
✔ Customer Engagement Rebuilt – New infrastructure for billing, reporting, and transactions established.
✔ Valuable Patient Data Secured – Historical clinical and genomic datasets now under Rhythm’s control.
What This Means for Rhythm
With the integration set to fully complete by the end of February, Rhythm is now focused on commercial expansion. The company sees significant opportunities for both geneType™ and ColoSTAT®, its flagship colorectal cancer diagnostic.
CEO Statement:
“We’ve made rapid progress integrating geneType™, allowing us to accelerate commercial growth. With key infrastructure and partnerships in place, we are well-positioned to expand our reach and drive adoption globally.”
A final update on the integration process will be provided in the coming weeks.
